The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages

Kevin Fabrizio, Catherine Manix, Haijun Tian, Nico van Rooijen, Liise-anne Pirofski

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The efficacy of antibody immunity against Streptococcus pneumoniae stems from the ability of opsonic, serotype (ST)-specific antibodies to pneumococcal capsular polysaccharide (PPS) to facilitate killing of the homologous ST by host phagocytes. However, PPS-specific antibodies have been identified that are protective in mice, but do not promote opsonic killing in vitro, raising the question of how they mediate protection in vivo. To probe this question, we investigated the dependence of antibody efficacy against lethal systemic (intraperitoneal, i.p.) infection with Streptococcus pneumoniae serotype 3 (ST3) on macrophages and neutrophils for the following PPS3-specific monoclonal antibodies (MAbs) in survival experiments in mice using a non-opsonic human IgM (A7), a non-opsonic mouse IgG1 (1E2) and an opsonic mouse IgG1 (5F6). The survival of A7- and PPS3-specific and isotype control MAb-treated neutrophil-depleted and neutrophil-sufficient and macrophage-depleted and macrophage-sufficient mice were determined after i.p. challenge with ST3 strains 6303 and WU2. Neutrophils were dispensable for A7 and the mouse MAbs to mediate protection in this model, but macrophages were required for the efficacy of A7 and optimal mouse MAb-mediated protection. For A7-treated mice, macrophage-depleted mice had higher blood CFU, cytokines and peripheral neutrophil levels than macrophage-sufficient mice, and macrophage-sufficient mice had lower tissue bacterial burdens than control MAb-treated mice. These findings demonstrate that macrophages contribute to opsonic and non-opsonic PPS3-specific MAb-mediated protection against ST3 infection by enhancing bacterial clearance and suggest that neutrophils do not compensate for the absence of macrophages in the model used in this study.

Original languageEnglish (US)
Pages (from-to)7542-7550
Number of pages9
JournalVaccine
Volume28
Issue number47
DOIs
StatePublished - Nov 3 2010

Fingerprint

Streptococcus pneumoniae
Polysaccharides
serotypes
macrophages
polysaccharides
Macrophages
antibodies
Antibodies
mice
neutrophils
Neutrophils
Serogroup
monoclonal antibodies
Immunoglobulin G
Monoclonal Antibodies
Pneumococcal Infections
Survival
phagocytes
Phagocytes
Bacterial Infections

Keywords

  • Macrophages
  • Mouse models of pneumococcal disease
  • Neutrophils
  • Non-opsonic antibodies
  • Opsonic antibodies
  • Phagocytes
  • Pneumococcal capsular polysaccharide
  • Pneumococcal capsular polysaccharide antibodies
  • Pneumococcal sepsis
  • Serotype 3 pneumococcus

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages. / Fabrizio, Kevin; Manix, Catherine; Tian, Haijun; van Rooijen, Nico; Pirofski, Liise-anne.

In: Vaccine, Vol. 28, No. 47, 03.11.2010, p. 7542-7550.

Research output: Contribution to journalArticle

Fabrizio, Kevin ; Manix, Catherine ; Tian, Haijun ; van Rooijen, Nico ; Pirofski, Liise-anne. / The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages. In: Vaccine. 2010 ; Vol. 28, No. 47. pp. 7542-7550.
@article{31401314898f4f6ebca576256f0c3d1d,
title = "The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages",
abstract = "The efficacy of antibody immunity against Streptococcus pneumoniae stems from the ability of opsonic, serotype (ST)-specific antibodies to pneumococcal capsular polysaccharide (PPS) to facilitate killing of the homologous ST by host phagocytes. However, PPS-specific antibodies have been identified that are protective in mice, but do not promote opsonic killing in vitro, raising the question of how they mediate protection in vivo. To probe this question, we investigated the dependence of antibody efficacy against lethal systemic (intraperitoneal, i.p.) infection with Streptococcus pneumoniae serotype 3 (ST3) on macrophages and neutrophils for the following PPS3-specific monoclonal antibodies (MAbs) in survival experiments in mice using a non-opsonic human IgM (A7), a non-opsonic mouse IgG1 (1E2) and an opsonic mouse IgG1 (5F6). The survival of A7- and PPS3-specific and isotype control MAb-treated neutrophil-depleted and neutrophil-sufficient and macrophage-depleted and macrophage-sufficient mice were determined after i.p. challenge with ST3 strains 6303 and WU2. Neutrophils were dispensable for A7 and the mouse MAbs to mediate protection in this model, but macrophages were required for the efficacy of A7 and optimal mouse MAb-mediated protection. For A7-treated mice, macrophage-depleted mice had higher blood CFU, cytokines and peripheral neutrophil levels than macrophage-sufficient mice, and macrophage-sufficient mice had lower tissue bacterial burdens than control MAb-treated mice. These findings demonstrate that macrophages contribute to opsonic and non-opsonic PPS3-specific MAb-mediated protection against ST3 infection by enhancing bacterial clearance and suggest that neutrophils do not compensate for the absence of macrophages in the model used in this study.",
keywords = "Macrophages, Mouse models of pneumococcal disease, Neutrophils, Non-opsonic antibodies, Opsonic antibodies, Phagocytes, Pneumococcal capsular polysaccharide, Pneumococcal capsular polysaccharide antibodies, Pneumococcal sepsis, Serotype 3 pneumococcus",
author = "Kevin Fabrizio and Catherine Manix and Haijun Tian and {van Rooijen}, Nico and Liise-anne Pirofski",
year = "2010",
month = "11",
day = "3",
doi = "10.1016/j.vaccine.2010.08.061",
language = "English (US)",
volume = "28",
pages = "7542--7550",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "47",

}

TY - JOUR

T1 - The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages

AU - Fabrizio, Kevin

AU - Manix, Catherine

AU - Tian, Haijun

AU - van Rooijen, Nico

AU - Pirofski, Liise-anne

PY - 2010/11/3

Y1 - 2010/11/3

N2 - The efficacy of antibody immunity against Streptococcus pneumoniae stems from the ability of opsonic, serotype (ST)-specific antibodies to pneumococcal capsular polysaccharide (PPS) to facilitate killing of the homologous ST by host phagocytes. However, PPS-specific antibodies have been identified that are protective in mice, but do not promote opsonic killing in vitro, raising the question of how they mediate protection in vivo. To probe this question, we investigated the dependence of antibody efficacy against lethal systemic (intraperitoneal, i.p.) infection with Streptococcus pneumoniae serotype 3 (ST3) on macrophages and neutrophils for the following PPS3-specific monoclonal antibodies (MAbs) in survival experiments in mice using a non-opsonic human IgM (A7), a non-opsonic mouse IgG1 (1E2) and an opsonic mouse IgG1 (5F6). The survival of A7- and PPS3-specific and isotype control MAb-treated neutrophil-depleted and neutrophil-sufficient and macrophage-depleted and macrophage-sufficient mice were determined after i.p. challenge with ST3 strains 6303 and WU2. Neutrophils were dispensable for A7 and the mouse MAbs to mediate protection in this model, but macrophages were required for the efficacy of A7 and optimal mouse MAb-mediated protection. For A7-treated mice, macrophage-depleted mice had higher blood CFU, cytokines and peripheral neutrophil levels than macrophage-sufficient mice, and macrophage-sufficient mice had lower tissue bacterial burdens than control MAb-treated mice. These findings demonstrate that macrophages contribute to opsonic and non-opsonic PPS3-specific MAb-mediated protection against ST3 infection by enhancing bacterial clearance and suggest that neutrophils do not compensate for the absence of macrophages in the model used in this study.

AB - The efficacy of antibody immunity against Streptococcus pneumoniae stems from the ability of opsonic, serotype (ST)-specific antibodies to pneumococcal capsular polysaccharide (PPS) to facilitate killing of the homologous ST by host phagocytes. However, PPS-specific antibodies have been identified that are protective in mice, but do not promote opsonic killing in vitro, raising the question of how they mediate protection in vivo. To probe this question, we investigated the dependence of antibody efficacy against lethal systemic (intraperitoneal, i.p.) infection with Streptococcus pneumoniae serotype 3 (ST3) on macrophages and neutrophils for the following PPS3-specific monoclonal antibodies (MAbs) in survival experiments in mice using a non-opsonic human IgM (A7), a non-opsonic mouse IgG1 (1E2) and an opsonic mouse IgG1 (5F6). The survival of A7- and PPS3-specific and isotype control MAb-treated neutrophil-depleted and neutrophil-sufficient and macrophage-depleted and macrophage-sufficient mice were determined after i.p. challenge with ST3 strains 6303 and WU2. Neutrophils were dispensable for A7 and the mouse MAbs to mediate protection in this model, but macrophages were required for the efficacy of A7 and optimal mouse MAb-mediated protection. For A7-treated mice, macrophage-depleted mice had higher blood CFU, cytokines and peripheral neutrophil levels than macrophage-sufficient mice, and macrophage-sufficient mice had lower tissue bacterial burdens than control MAb-treated mice. These findings demonstrate that macrophages contribute to opsonic and non-opsonic PPS3-specific MAb-mediated protection against ST3 infection by enhancing bacterial clearance and suggest that neutrophils do not compensate for the absence of macrophages in the model used in this study.

KW - Macrophages

KW - Mouse models of pneumococcal disease

KW - Neutrophils

KW - Non-opsonic antibodies

KW - Opsonic antibodies

KW - Phagocytes

KW - Pneumococcal capsular polysaccharide

KW - Pneumococcal capsular polysaccharide antibodies

KW - Pneumococcal sepsis

KW - Serotype 3 pneumococcus

UR - http://www.scopus.com/inward/record.url?scp=77958197452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958197452&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.08.061

DO - 10.1016/j.vaccine.2010.08.061

M3 - Article

VL - 28

SP - 7542

EP - 7550

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 47

ER -